

1 HONORABLE RONALD B. LEIGHTON  
2  
3  
4  
5  
6  
7  
8

UNITED STATES DISTRICT COURT  
WESTERN DISTRICT OF WASHINGTON  
AT TACOMA

9 UNITED STATES OF AMERICA,

10 v. Plaintiff,

11 ANTHONY BALLENGER,

12 Defendant.

CASE NO. CR16-5535RBL

ORDER

14 THIS MATTER is before the Court on Defendant's Emergency Motion for  
15 Compassionate Release Pursuant to 18 U.S.C. § 3582(c)(1). [Dkt. #306]. The Court has  
16 reviewed the materials filed for and against said motion. Oral argument is not necessary. For  
17 the reasons stated below, the motion is **DENIED**.

18 **I. FACTS**

19 On June 16, 2017, this Court sentenced Anthony Ballenger ("Ballenger") to a  
20 seventy-six (76) month term of imprisonment following his guilty pleas to charges of  
21 unauthorized access to a protected computer, aggravated identity theft, and conspiracy to  
22 distribute oxycodone. *See* Judgment, Dkt. 139. Ballenger devised and led a sophisticated  
23 prescription-forgery conspiracy that relied on digital crimes, identity theft, and an opioid-  
24

1 distribution network. Ballenger's criminal history consists of other identity theft and  
2 drug offenses, including a 2009 conviction for stealing his employer's car, installing  
3 flashing lights, impersonating a law enforcement officer, and pulling over civilians.

4 Ballenger is currently serving his term of imprisonment at Terminal Island FCI.  
5 His expected release date is January 27, 2023.

6 **A. Ballenger's Motion**

7 On May 11, 2020, Ballenger filed a *pro se* Motion for Compassionate Release.  
8 [Dkt. #301]. Following the appointment of CJA counsel James Feldman, Ballenger's  
9 appointed counsel filed a second Motion seeking the same relief. For simplicity,  
10 Ballenger's two motions seeking the same relief are collectively referred to herein as the  
11 "Motion."

12 Ballenger claims he is entitled to compassionate release because of complications  
13 arising from Crohn's disease, urinary tract infections, and bladder disease. As his  
14 medical records reflect, Ballenger has received extensive medical treatment for all of  
15 these conditions throughout his time as a federal inmate, but has not sought  
16 compassionate release before this year.

17 Ballenger asserts that his conditions place him at greater risk of contracting  
18 COVID-19. Specifically, relying on the declaration of Doctor Marc Stern, a correctional  
19 health care consultant, Ballenger claims that his consumption of an immunosuppressant  
20 to treat his Crohn's Disease places him at higher risk of contracting COVID-19. His  
21 medical records show that he tested positive for COVID-19 on April 23, 2020 and later  
22

1 tested negative on May 13, 2020, which suggests that he has contracted and recovered  
2 from the virus since the outbreak began.

3 Ballenger also asserts that he cannot receive adequate treatment for his medical  
4 conditions because the medical system is overburdened by the needs of COVID-19  
5 patients. He refers to a purported episode in which the Bureau of Prisons (BOP) failed to  
6 provide him with medicine to treat kidney stones. In actuality, his medical records show  
7 that he consistently has received care from qualified medical providers after seeking  
8 medical attention.

9 Ballenger's Motion does not cite any other facts that support his request for  
10 compassionate release. Indeed, he acknowledges that he is only "33 years old", and that  
11 the BOP's medical system has repeatedly treated his recurring medical conditions.  
12 Following the most recent medical encounter set forth in his medical records, the  
13 physician who treated Ballenger noted that he "appears well," is "alert and oriented," that  
14 his nutrition was "within normal limits." The physician also noted that Ballenger's  
15 pulmonary, cardiovascular, abdominal, and gastrointestinal functions were normal.

## 17 II. ANALYSIS

### 18 A. The Legal Standards for Compassionate Release

19 As amended by the First Step Act of 2018, 18 U.S.C. § 3582(c)(1)(A) now permits  
20 an inmate satisfying certain conditions to file a motion with the district court seeking  
21 "compassionate release." As relevant to the defendant's motion, the statute now reads:

22 (c) The court may not modify a term of imprisonment once it has been  
23 imposed except that—

(1) in any case—

(A) the court, upon motion of the Director of the Bureau of Prisons, or upon motion of the defendant after the defendant has fully exhausted all administrative rights to appeal a failure of the Bureau of Prisons to bring a motion on the defendant's behalf or the lapse of 30 days from the receipt of such a request by the warden of the defendant's facility, whichever is earlier, may reduce the term of imprisonment (and may impose a term of probation or supervised release with or without conditions that does not exceed the unserved portion of the original term of imprisonment), after considering the factors set forth in section 3553(a) to the extent that they are applicable, if it finds that—

(i) extraordinary and compelling reasons warrant such a reduction; or

\* \* \*

and that such a reduction is consistent with applicable policy statements issued by the Sentencing Commission; . . . .

18 U.S.C. § 3582(c)(1)(A). Congress directed the Sentencing Commission to draft the policy statement referenced in this statute in 28 U.S.C. § 994(f), which statute provides:

The Commission, in promulgating general policy statements regarding the sentencing modification provisions in section 3582(c)(1)(A) of title 18, shall describe what should be considered extraordinary and compelling reasons for sentence reduction, including the criteria to be applied and a list of specific examples. Rehabilitation of the defendant alone shall not be considered an extraordinary and compelling reason.

That policy statement, found at USSG § 1B1.13, provides:

Upon motion of the Director of the Bureau of Prisons under 18 U.S.C. § 3582(c)(1)(A), the court may reduce a term of imprisonment (and may impose a term of supervised release with or without conditions that does not exceed the unserved portion of the original term of imprisonment) if, after considering the factors set forth in 18 U.S.C. § 3553(a), to the extent that they are applicable, the court determines that—

(1) (A) Extraordinary and compelling reasons warrant the reduction;

(B) The defendant (i) is at least 70 years old; and (ii) has served at least 30 years in prison pursuant to a sentence imposed under 18 U.S.C. § 3559(c) for the offense or offenses for which the defendant is imprisoned;

(2) The defendant is not a danger to the safety of any other person or to the community, as provided in 18 U.S.C. § 3142(g); and

(3) The reduction is consistent with this policy statement.

As directed by 28 U.S.C. § 924(t), the Application Notes define what constitute “extraordinary and compelling reasons” to support a reduction in sentence. Specifically, application note 1 provides that extraordinary and compelling reasons exist under the following circumstances:

(A) Medical Condition of the Defendant.—

(i) The defendant is suffering from a terminal illness (i.e., a serious and advanced illness with an end of life trajectory). A specific prognosis of life expectancy (i.e., a probability of death within a specific time period) is not required. Examples include metastatic solid-tumor cancer, amyotrophic lateral sclerosis (ALS), end-stage organ disease, and advanced dementia.

(ii) The defendant is—

(I) suffering from a serious physical or medical condition,

(II) suffering from a serious functional or cognitive impairment, or

(III) experiencing deteriorating physical or mental health because of the aging process.

that substantially diminishes the ability of the defendant to provide self-care within the environment of a correctional facility and from which he or she is not expected to recover.

(B) Age of the Defendant.--The defendant (i) is at least 65 years old; (ii) is experiencing a serious deterioration in physical or mental health because of

1 the aging process; and (iii) has served at least 10 years or 75 percent of his or  
2 her term of imprisonment, whichever is less

3 USSG § 1B1.13 cmt. n.1.

4 The Application Note also provides that extraordinary and compelling reasons  
5 may include certain described family circumstances, or other reasons as determined by  
6 the Director of the Bureau of Prisons. USSG § 1B1.13 cmt. n.1. The Application Notes  
7 then state that “[t]he court is in a unique position to determine whether the circumstances  
8 warrant a reduction (and, if so, the amount of reduction), after considering the factors set  
9 forth in 18 U.S.C. § 3553(a) and the criteria set forth in this policy statement, such as the  
10 defendant’s medical condition, the defendant’s family circumstances, and whether the  
11 defendant is a danger to the safety of any other person or to the community.” USSG §  
12 1B1.13 cmt. n.4.

13 ***1. The Policy Statement at USSG § 1B1.13 Is Binding.***

14 Based on the text of § 3582(c)(1)(A), the policy statement referenced in §  
15 3582(c)(1), like that referenced in 18 U.S.C. § 3582(c)(2), *see* USSG § 1B1.10, is binding  
16 on this Court and controls how this Court is to exercise of discretion. *Cf. Dillon v. United*  
17 *States*, 560 U.S. 817, 827 (2010). In *Dillon*, the Supreme Court addressed the identical  
18 language if “such a reduction is consistent with applicable policy statements issued by the  
19 Sentencing Commission” contained in 18 U.S.C. § 3582(c)(2). The Court held that based  
20 on this language, the Commission’s pertinent policy statement is binding on district  
21 courts and any limitations contained in that Guideline is a limitation a district court’s  
22 discretion to reduce sentences. *See Dillon*, 560 U.S. at 826. The Court emphasized that a  
23

1 sentence reduction under Section 3582(c)(2) “represents a congressional act of lenity  
2 intended to give prisoners the benefit of later enacted adjustments to the judgments  
3 reflected in the Guidelines.” *Id.* at 828.

4 Section 3582(c)(1)(A), like the companion statutory provision addressed in Dillon,  
5 also rests on a limited act of Congressional lenity. And both subsections follow the same  
6 prefatory language of Section 3582(c) that makes unassailably clear that a court may only  
7 “modify a term of imprisonment once it has been imposed” under the limited  
8 circumstances set out in these two subsection. Given the parallel nature of the two  
9 provisions, there is no reason to conclude that the policy statement applicable to §  
10 3582(c)(1)(A) is other than binding.

12 The fact that USSG § 1B1.13 has not been amended after enactment of the First  
13 Step Act does not alter that conclusion. Although the First Step Act removed the  
14 limitation that a motion could only be filed by the Director of the Bureau of Prisons, that  
15 did not change any of the statutory standards for relief, or suggest that there should be a  
16 broader interpretation of what constitutes an “extraordinary and compelling reason”  
17 beyond what is stated in the policy statement. Nor did Congress direct the Sentencing  
18 Commission to change or expand this policy statement. Rather, Congress simply made it  
19 possible for a defendant to file a motion rather than retaining the Bureau of Prisons as the  
20 gatekeeper. *See United States v. Ebbers*, 2020 WL 91399, \*4 (S.D.N.Y. Jan. 8, 2020)  
21 (“Congress in fact only expanded access to the courts; it did not change the standard.”).  
22

23 As such numerous courts have found, this policy statement is still binding  
24 and must guide this Court’s determination of whether the facts that the defendant

1 has presented constitute “extraordinary and compelling reasons” and what situations  
2 other than a defendant’s medical condition might constitute such a reason (citations  
3 omitted).

4        Regardless of whether it is binding, courts have observed that the guidance is  
5 helpful regarding what circumstances constitute extraordinary and compelling reason to  
6 disturb the finality of a sentence. *See, e.g., United States v. Mitchell*, No. 2:12-CR-0401  
7 KJM, 2020 WL 2770070, at \*2 (E.D. Cal. May 28, 2020); *United States v. Esparza*, No.  
8 1:07-CR-00294-BLW, 2020 WL 1696084, at \*2 n.2 (D. Idaho Apr. 7, 2020); *United*  
9 *States v. Gonzalez*, No. 2:18-CR-0232-TOR-15, 2020 WL 1536155, at \*2 (E.D. Wash.  
10 March 31, 2020); *United States v. Rivernider*, 2019 WL 3816671, at \*2 (D. Conn. Aug.  
11 14, 2019. This is particularly true where Congress chose not to disturb this policy  
12 statement or expand the understanding of what constitutes extraordinary and compelling  
13 circumstances when it amended this provision in the First Step Act.

15        Thus, before this Court may reduce the defendant’s sentence, applying the  
16 guidance in USSG § 1B1.13, this court first must determine whether the reasons the  
17 defendant has provided are “extraordinary and compelling.” And if the court concludes  
18 such a reason or reasons have been provided, this Court must then consider whether a  
19 reduction in sentence is appropriate in light of the factors in 18 U.S.C. § 3553(a) and the  
20 danger that the defendant might continue to present to another person or the community.

22 **B. Ballenger Has Not Met the Standard for a Reduction in Sentence.**

23        Because more than thirty days have passed since Ballenger made his request for  
24 compassionate release to the warden on January 17, 2020, this statutory prerequisite has

1 been met. But having passed this hurdle is only step one. To qualify for a sentence  
2 reduction, Ballenger still bears the burden to show “extraordinary and compelling  
3 reasons” that meet the high bar set by Congress and the Sentencing Commission for  
4 compassionate release to be granted in order to be eligible for a district court’s  
5 discretionary consideration of a reduced sentence under this provision. *See Riley v.*  
6 *United States*, No. C19-1522 JLR, 2020 WL 1819838 at \*7 (W.D. Wash. Apr. 10, 2020);  
7 *United States v. Greenhut*, 2020 WL 509385, at \*1 (C.D. Cal. Jan. 31, 2020) (holding  
8 that defendant bears the burden of establishing entitlement to sentencing reduction and  
9 citing *United States v. Sprague*, 135 F.3d 1301, 1306-07 (9th Cir. 1998)).

10  
11 As set out above, Ballenger relies on two facts in support of his request for a  
12 sentence reduction: (1) his chronic medical conditions, which Ballenger claims cannot  
13 adequately be treated by the BOP’s medical system; and (2) the increased risk of COVID  
14 19 posed by Ballenger’s consumption of an immunosuppressant to treat his Crohn’s  
15 disease. Neither fact comes close to being an “extraordinary and compelling”  
16 circumstance that warrants compassionate release.

17 ***1. Ballenger’s Health Conditions.***

18 While Ballenger’s chronic medical conditions warrant sympathy, they do not give  
19 rise to the extraordinary and compelling reasons necessary to justify a sentence reduction.  
20 As Ballenger explains, he suffers from Crohn’s disease and persistent bladder conditions  
21 that have required the use of different types of catheters over the last several months.  
22 These indisputably are chronic conditions that have caused Ballenger significant distress,  
23 but they do not meet the standard for compassionate release. As the court explained in

1     *United States v. Ayon-Nunez*, “[t]o be faithful to the statutory language requiring  
2     ‘extraordinary and compelling reasons,’ it is not enough that Defendant suffers from . . .  
3     chronic conditions that [he] is not expected to recover from. In general, **chronic**  
4     **conditions that can be managed in prison are not a sufficient basis for compassionate**  
5     **release.**” 2020 WL 704785, at \*2–3 (E.D. Cal. Feb. 12, 2020) (emphasis added)  
6     (rejecting a claim for compassionate release from a defendant suffering from severe back  
7     injuries and epilepsy); *United States v. Christopher Luck*, 2020 WL 3050762, at \*2 (N.D.  
8     Cal. June 8, 2020) (same); *Riley v. United States*, 2020 WL 1819838, at \*7 (W.D. Wash.  
9     Apr. 10, 2020)*United States v. Mangarella*, 2020 WL 1291835, at \*2–3 (W.D.N.C. Mar.  
10     16, 2020) (“[A] compassionate release . . . is an extraordinary and rare event.” (citation  
11     omitted)).

13         The BOP’s medical staff obviously can (and has) managed Ballenger’s chronic  
14     medical conditions. Ballenger’s medical records show that he has had these conditions  
15     throughout his time in federal custody. As Ballenger acknowledges, BOP has  
16     hospitalized him “numerous times” for these conditions, and has treated him using a  
17     variety of techniques, including two different types of catheters. His medical records  
18     reflect the effectiveness of BOP’s treatment regime in ensuring that Ballenger is able to  
19     continue to reside in federal prison facilities and participate in prison programming.  
20         Notably, in the most recent medical visit documented in Ballenger’s medical records, the  
21     treating physician found that Ballenger’s pulmonary, cardiovascular, and gastrointestinal  
22     conditions were normal.  
23

1       In short, Ballenger’s chronic conditions do not come close to the standard for  
2 “extraordinary circumstances” that other courts have applied when granting motions  
3 for compassionate release. *See United States v. Johns*, 2019 WL 2646663, at \*2–3  
4 (D. Ariz. June 27, 2019) (granting reduction after 23 years of imprisonment for 81-  
5 year-old defendant with multiple serious medical conditions, including “severe  
6 heart disease” and a stroke from which he was not likely to recover, who had  
7 substantially diminished ability to provide self-care within the BOP). As those other  
8 courts have explained, viewing compassionate release too expansively could yield  
9 significant sentencing disparities. *Ebbers*, 2020 WL at \*6 (S.D.N.Y. Jan. 8, 2020).  
10  
11      Compassionate release is not a tool to “correct” a judgment. *Id.* Courts have  
12 generally recognized that “it is a rare case in which health conditions present an  
13 ‘exceptional reason’” to allow for release where detention would otherwise be  
14 warranted. *See, e.g., United States v. Wages*, 271 F. App’x 726, 728 (10th Cir. 2008)  
15 (citing various pre-trial detention cases).

16       Finally, Ballenger’s suggestion that BOP’s medical staff is too “overwhelmed” to  
17 treat his conditions as a result of demands imposed by the COVID-19 outbreak is  
18 baseless. Nothing in his medical records reflects that BOP medical staff was ineffective  
19 or tardy in treating his medical conditions.

20       **2. COVID-19 and the BOP Efforts to Address the Spread of This Disease.**

21       Ballenger also cites his use of immunosuppressant drugs as a basis for  
22 release. Ballenger’s worry about contracting COVID-19 is certainly understandable,  
23 but his medical records show that he has already contracted and recovered from the

1 virus. Moreover, because of the COVID-19 pandemic, BOP is using its authorities  
2 under 18 U.S.C. § 3624(c)(2) and 34 U.S.C. § 60541(g) to reduce the inmate  
3 population and to place qualifying particularly vulnerable inmates into home  
4 confinement. The Attorney General issued directives to BOP on March 26 and April  
5 3, 2020, to begin reviewing all inmates who have COVID-19 risk factors, as  
6 described by the Centers for Disease Control and Prevention (CDC), to determine  
7 which inmates would be suitable for release to home confinement to protect the  
8 health and safety of both inmates and personnel at BOP institutions.  
9

10 BOP has implemented measures to mitigate the spread of COVID-19 among  
11 federal inmates, including through increased testing. Moreover, as reflected by his  
12 medical records, in the four months since the start of the COVID-19 outbreak,  
13 Ballenger has already contracted and recovered from COVID-19. Thus, Ballenger's  
14 use of immunosuppressants is not an extraordinary and compelling reason for early  
15 release.

16 ***3. FCI Terminal Island and Ballenger's Status.***

17 The United States acknowledges that Ballenger is being held at one of the BOP  
18 facilities which has experienced an outbreak of COVID-19. Indeed, much of the motion  
19 is directed at conditions at FCI Terminal Island where the defendant is currently housed.  
20 Pointing to the class action law suit and habeas petition filed by three inmates at FCI  
21 Terminal Island and the self-serving declarations that were attached, *see Wilson v. Ponce*,  
22 20-CV-4451-MWF-MRW, (C.D. Cal.), the defense argues that this establishes that he is  
23 at great risk if this Court does not grant his motion for release. What is absent from that  
24

1 recital is any discussion of significant efforts that have been made at this and other BOP  
2 institutions to ensure the health and safety of inmates in BOP care.

3       The declaration by Ronell Prioleau, the Associate Warden at FCI Terminal Island,  
4 attached to the respondent's opposition to the motion for a temporary restraining order  
5 and preliminary injunction provides extensive details regarding the efforts made to  
6 address the COVID-19 pandemic. The declaration describes in detail all the specific  
7 steps taken at Terminal Island to stop the spread of this virus. One step has been  
8 screening. Since early March, 2020, all arriving inmates both for COVID-19 symptoms,  
9 and for exposure risk factors such as whether the inmate had traveled through an area  
10 where COVID-19 was known to be rapidly spreading. Inmates were then quarantined for  
11 14 days before being released to the general population.

13       Further, all inmates at the institution have been screened for illness at least daily  
14 through the use of temperature and symptom checks. The same is true for staff and any  
15 visitors permitted onto the facility. And, through increased testing equipment the facility  
16 has obtained and assistance from the Los Angeles County Department of Public Health,  
17 all inmates at this institution have been tested at least once for COVID-19. Although,  
18 this has resulted in the discovery of a significant number individuals who have tested  
19 positive for the disease, it also assisted in disease control since it allowed for the  
20 identification of asymptomatic individuals who could spread the disease. As a result, as  
21 of June 1, 2020, of the 1002 inmates housed at this facility, 26 are listed as testing  
22 positive, and 663 are described as recovered. Sadly during the course of the last three  
23

1 months, 9 inmates have died. And inmates testing positive are obviously quarantined and  
2 their health monitored.

3 Beyond screening and testing, a number of other measures also have been taken.  
4 The institution has made sure that inmates have access to sinks, water, and soap at all  
5 times. Common areas are disinfected daily and cleaning supplies are stocked for use for  
6 that purpose and for inmates to use in cleaning their cells. Inmates are provided one  
7 surgical mask per week and three cloth masks which they are required to wear.  
8 Similarly, staff receive two surgical masks and three cloth masks which they are required  
9 to wear.

10 As further support for his motion, the defendant also cites the decisions by the  
11 district court in litigation regarding FCI Elkton in the Northern District of Ohio. *See*  
12 *Wilson v. Williams*, 20-Civ-794, Dkt. 1, (N.D. Ohio). In its initial order, the district court  
13 directed the BOP to evaluate each inmate exhibiting a risk factor identified by the Centers  
14 for Disease Control and Prevention (CDC) to determine their eligibility for  
15 compassionate release, parole or community supervision, transfer furlough, or non-  
16 transfer furlough. *Wilson v. Williams*, 2020 WL 1940882, at \*11 (N.D. Ohio Apr. 22,  
17 2020). As noted by the defense, the Sixth Circuit denied the government's motion to stay  
18 this order and the Supreme Court declined to "stay the District Court's April 22  
19 preliminary injunction without prejudice to the Government seeking a new stay if  
20 circumstances warrant." *Williams v. Wilson*, \_ S. Ct.\_, 2020 WL 2644305 (May 26,  
21 2020). However, the Court did not deny the stay of the merits but rather declined to issue  
22 a stay because the district court had issued a new May 19, 2020 order enforcing the  
23  
24

1 injunction and imposing new measures which the government had not yet appealed. That  
2 appeal has since been filed. *Williams v. Wilson*, Sixth Circuit Case No. 20-3547. And  
3 while the Sixth Circuit again denied a stay, on June 4, 2020, the Supreme Court entered  
4 an order staying both district court ordered pending the government's appeal. *See*  
5 *Williams v. Wilson*, Case No. 19A1047.

6 But at bottom, the ongoing litigation regarding FCI Elkton and FCI Terminal  
7 Island does not purport to resolve the question of whether an individual defendant is  
8 eligible for compassionate release. Rather, however, that the principal questions at issue  
9 in both the cases is the jurisdiction to enter the orders entered and requested which  
10 essentially seek changes regarding the management of the prison. Thus, this litigation  
11 adds little to this issue before this Court.

13 ***A. The § 3553(a) Factors Don't Support the Defendant's Release and the***  
***Defendant Has Failed to Establish He is No Longer a Danger***

14 In any event, having risk factors for COVID-19 is not the only factor that this  
15 Court must consider. Rather, even if the Court concludes that the defendant's medical  
16 issues coupled with the existence of COVID-19 at the institution, constitute extraordinary  
17 and compelling circumstances, this court must still determine whether a reduction in  
18 sentence is warranted by applying the factors in 18 U.S.C. § 3553(a) along with  
19 consideration of whether this defendant continues to present a danger to the community.  
20 Here, every one of those factors weighs against Ballenger's release.

22 In his motion, Ballenger minimizes his extensive criminal history and claims  
23 he poses no danger to the community. In truth, Ballenger's role as the leader of a  
24

1 sophisticated prescription-forgery and opioid-distribution scheme resulted in the  
2 distribution of tens of thousands of Oxycodone pills to users in this District. The  
3 offense contributed to addiction, health hazards, and the degradation of  
4 communities. Ballenger's use of sophisticated tools, including identity theft and  
5 unauthorized computer access, to carry out the scheme also compromised innocent  
6 doctors, pharmacies, and prescription-delivery networks.

7 Ballenger's lengthy criminal history reveals that he is a recidivist with the  
8 potential to engage in other crimes upon his release from custody. Ballenger's prior  
9 convictions include the violation of a no-contact order, fourth-degree assault, criminal  
10 impersonation of a law-enforcement officer, and a separate state-law conviction for  
11 forging prescriptions. Although he claims that he is not a violent offender, the offense  
12 conduct giving rise to those prior convictions reveals that he has a history of sociopathic  
13 behavior and no respect for the rule of law. Indeed, he committed the offenses giving rise  
14 to this conviction *while serving a term of community custody* under Washington State's  
15 Drug Offender Sentencing Alternative program. His track record simply does not support  
16 his claim that he is entitled to be placed on supervised release in lieu of serving the  
17 second half of his term of imprisonment.

18 The applicable Sentencing Guidelines range and concerns about sentencing  
19 disparity also weigh against Ballenger's motion. As set out in the government's  
20 sentencing memorandum, Ballenger's sentencing guidelines range was 151-188  
21 months; his seventy-six month term of imprisonment already falls well below the  
22 low end of that range. Moreover, Ballenger's deputy in the conspiracy, Stosh  
23

Satkowski, was sentenced to an eighty-four month term of imprisonment on January 5, 2018. Thus, if this Court were to release Ballenger now, he would effectively have served a term of imprisonment that is a mere quarter of the length of the low end of his guideline range and substantially below the term of imprisonment being served by his primary co-conspirator. The Court will not accede to Ballenger's wishes.

### III. CONCLUSION

For all of these reasons, Ballenger's Motion for Compassionate Release [Dkt. #306] is **DENIED**.

Dated this 26<sup>th</sup> day of June, 2020.

Ronald B. Leighton  
Ronald B. Leighton  
United States District Judge